FDA Promotes Personalized Medicine - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Promotes Personalized Medicine

FDA is undertaking a spectrum of initiatives to encourage the development of drugs and medical products linked to patient subtypes. At a briefing to unveil a new report on these activities, commissioner Margaret Hamburg discussed how a deeper understanding of the underlying mechanisms of disease has made it possible for FDA to approve new cancer drugs for patients with specifically characterized tumors, as well as a new treatment for cystic fibrosis effective in patients with a specific gene mutation. Agency researchers are developing methods for refining dosing regimens by examining genetic factors that may affect how much of a drug enters the blood stream. Richard Pazdur, director of FDA’s Center for Drug Evaluation and Research’s Office of Oncology & Hematology products, predicted that smaller clinical trials for targeted cancer treatments will be possible by using platforms for universal testing of known biomarkers. “Paving the Way for Personalized Medicine” is available at www.fda.gov.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here